• Police seek suspects in deadly birthday party shooting
  • Lawmakers launch inquires into U.S. boat strike
  • Nov. 29, 2025, 10:07 PM EST / Updated Nov. 30, 2025,…
  • Mark Kelly says troops ‘can tell’ what orders…

Be that!

contact@bethat.ne.com

 

Be That ! Menu   ≡ ╳
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics Politics
☰

Be that!

AI security system mistakes teen's bag of chips as gun

admin - Latest News - October 27, 2025
admin
22 views 7 secs 0 Comments



AI security system mistakes teen’s bag of chips as gun



Source link

TAGS:
PREVIOUS
Student tries to leave Jamaica ahead of hurricane
NEXT
Savewith a NBCUniversal ProfileCreate your free profile or log in to save this articleOct. 27, 2025, 1:58 PM EDTBy Rebecca ShabadPresident Donald Trump revealed Monday that he underwent magnetic resonance imaging during his visit to Walter Reed National Military Medical Center earlier this month. Trump, 79, didn’t disclose the purpose of the MRI, saying only that it was “perfect.” The White House previously said only Trump underwent “advanced imaging” during the evaluation.”I gave you the full results,” Trump told reporters aboard Air Force One on the way to Japan when asked if he had received one that day. “We had an MRI, MRI and the machine, you know, the whole thing, and it was perfect.”When asked for additional details, Trump said “you can ask the doctors,” adding, “I think they gave you a very conclusive — nobody has ever given you reports like I gave you, and if I didn’t think it was going to be good, either I would let you know negatively, I wouldn’t run, I’d do something. But the doctors said some of the best reports for the age, some of the best reports they’ve ever seen.”The White House didn’t immediately respond to a request for comment Monday. The White House described the visit, which came after Trump’s annual physical exam in April, as a “follow-up evaluation” at the time and released a memo by the president’s doctor, Sean Barbabella. The president’s visit was “part of his ongoing health maintenance plan and included advanced imaging, laboratory testing and preventive health assessments conducted by a multidisciplinary team of specialists,” the doctor wrote. The summary also said Trump received flu and Covid shots, but much of the health information was vague and did not mention the president had received an MRI specifically or the reason for the imaging. The doctor concluded Trump is “in exceptional health, exhibiting strong cardiovascular, pulmonary, neurological, and physical performance.” Trump’s health has come under scrutiny in recent months after he has been seen with a bruise on the back of his right hand, often covered in makeup, and swelling in his lower legs. Officials said in February that the bruise was caused by the president’s “constantly working and shaking hands all day every day.”Trump’s doctor said in July that the president takes aspirin as part of a “cardiovascular prevention regimen” and that the bruising is a side effect. The swelling in the president’s legs was caused by “chronic venous insufficiency,” White House press secretary Karoline Leavitt said at the time. She called it a “benign” condition common in older men and added that tests found no evidence of a serious condition, such as deep vein thrombosis.Trump’s physical in April found that his heart, lungs, eyes, hearing and abdominal exam results were normal, and lab work appeared within the typical ranges for blood count, kidney, liver and thyroid tests, although his blood pressure was slightly elevated and he remained overweight.Rebecca ShabadRebecca Shabad is a politics reporter for NBC News based in Washington.
Related Post
October 20, 2025
Oct. 20, 2025, 1:45 PM EDTBy David CoxPeople with a leading cause of blindness were able to read again thanks to a tiny wireless chip implanted in the back of the eye and specialized augmented glasses, according to study results published Monday in the New England Journal of Medicine. The trial involved 38 European patients, all of whom had an advanced stage of dry age-related macular degeneration (AMD) known as geographic atrophy. There is no cure for AMD, which is driven by changes in a part of the retina called the macula and caused by inflammation and a build-up of waste. The photoreceptor cells in the macula are responsible for producing sharp, detailed and colored vision. When the disease has progressed to the geographic atrophy stage, these cells deteriorate and die, and people lose their central vision — meaning that an object straight ahead may appear blurry or covered up with a dark blotch. Roughly 22 million people in the U.S. have AMD, and about 1 million have geographic atrophy, according to the American Macular Degeneration Foundation.In the study, the participants, who had an average age of 79, were fitted with the “PRIMA device,” a system meant to replicate vision. Patients wear augmented reality glasses embedded with a camera that captures their visual field. What the camera “sees” is transmitted to the chip implanted in their eye in the form of infrared light. The chip converts the light into an electrical current, which stimulates the remaining healthy cells in the macula in a realistic way, enabling signals these cells send to be interpreted by the brain as vision. An image processor, which the user must carry, lets patients zoom in and magnify the images they see, which appear in black and white.The image on the right shows what the camera sends to the user’s implanted microchip.Science Corporation With the help of the PRIMA device, 80% of the 32 patients who returned for a reassessment one year after the chip implantation had achieved clinically meaningful visual improvements. Patients did experience side effects, predominantly related to the surgical procedure: The study reported that 26 serious adverse events occurred in 19 of the patients, ranging from elevated blood pressure in the eye to an accumulation of blood around the retina. The majority of the adverse events resolved within two months of the implantation. “It’s the first ever therapeutic approach that has led to an improvement in visual function in this group of patients,” said Dr. Frank Holz, the trial’s lead investigator and chair of the department of ophthalmology at the University Hospital of Bonn in Germany. “Late-stage age-related macular degeneration is a dismal disease. Patients are no longer capable of reading, driving a car, watching TV or even recognizing faces. So [these results] are a game-changer in my mind.”One patient, Sheila Irvine, 70, who was fitted with the PRIMA device at Moorfields Eye Hospital in London, said in a statement provided by the hospital that her life before receiving the implant was akin to “having two black discs in my eyes, with the outside distorted.” A self-described “avid bookworm” before losing her vision, Irvine said she was now able to do crosswords and read prescriptions.Dr. Sunir Garg, professor of ophthalmology at the retina service of Wills Eye Hospital in Philadelphia, who was not involved in the study, said the results represent a breakthrough for patients with geographic atrophy. All doctors have been able to offer, he said, are visual aids, like magnifiers, and emotional support.“Even with new medical therapies, the best that we can do is slow it down,” said Garg, who works with several drugmakers involved in treatments for AMD, including Apellis Pharmaceuticals, the maker of pegcetacoplan. That drug, which slows the progression of geographic atrophy, was recently approved in the U.S. and must be injected into the eye every 1 to 2 months. “We can’t stop it, and we can’t do anything to bring back lost vision.” An actor wearing the PRIMA system glasses.Science CorporationDr. Demetrios Vavvas, director of the retina service at Mass Eye and Ear in Boston, who was also not involved in the study, said that the PRIMA system is not without limitations. Vavvas noted that the surgery required to implant the chip in the eye requires a high level of surgical skill and is not without risk. “You have to lift the retina off its normal position to implant this device, which increases the atrophy,” said Vavvas, who is a consultant to Sumitomo Pharmaceuticals, a company working on stem cell therapies for patients with other forms of vision loss. Vavvas said it was important to note that the device isn’t restoring normal vision, as patients were only able to see in black and white rather than color, and the trial participants had to undergo a significant amount of training in order to learn how to see with the PRIMA device. He also said that it wasn’t clear whether the enhancements in visual ability had significantly improved the patients’ quality of life.But at the same time, Vavvas was also optimistic about its future potential, describing the current iteration of PRIMA as a key stepping stone in the field of vision restoration. “Think of this device as the pre-release iPhone,” he said. “The limitations are clear. We shouldn’t oversell that the quality of life really improved. But there were certain [visual] tasks at which the patients were clearly better. So it shows to us that there is potential in this approach. It is still in some ways, a prototype. They’re working on iterations of this device that will be better.”New upgrades to the PRIMA device could be coming in the next couple of years. The PRIMA system was invented by Stanford University ophthalmology professor Daniel Palanker and is being developed by the California-based neural engineering company Science Corporation.Palanker said technical improvements are being made to increase the number of pixels in the chip from 400 to 10,000. The new chips have already been tested in rats, and the upgraded chips are being manufactured for future human trials. With the aid of the camera’s zoom function, Palanker said that this could theoretically enable patients to achieve 20/20 visual resolution.The microchip shown next to a penny.Science Corporation“We are also working on next generation software that will allow patients to perceive not just black-and-white text, but also grey-scale natural images, such as faces,” Palanker said.Palanker suggested that the technology could be trialed in other retinal diseases that cause blindness, such as Stargardt disease, which has similar symptoms to age-related macular degeneration but is genetic and usually affects younger people. Garg and Vavvas are eager to see larger trials that provide more details about how the device improves patients’ ability to function on a day-to-day basis. Vavvas suggested that future trials should include a control arm to understand the extent to which the device yields real-world benefits, for example compared to existing electronic magnifiers. “Is it something that is good enough for patients to say, ‘Well, I’ve regained my independence because I can now do my credit card bills myself, stamp and address my envelopes myself, and look at grocery store labels?’” Garg said. “Those kinds of practical things I would like to know more about.”“This is a chronic disease that you will have for life, so we need more than one year of follow-up to see other risks, other problems,” Vavvas said. “Does that signal of efficacy that we see at 12 months, remain two years later?”While Vavvas said he would not call the device a complete panacea for blindness, the study showed that brain-computer interfaces can represent an important approach to tackling different kinds of severe visual impairment. “As the iterations of this device become better and better, it could become a real solution for a cohort of patients,” he said. David CoxDavid Cox is a freelance journalist focusing on all aspects of health, from fitness and nutrition to infectious diseases and future medicines. Prior to becoming a full-time journalist, he was a neuroscientist attempting to understand how and why the brain goes wrong.
October 15, 2025
Trump Threatens to Cut More Jobs as Shutdown Enters Day 15
October 18, 2025
Oct. 18, 2025, 7:45 AM EDTBy Max GaoEthan Hawke and Richard Linklater have one of the all-time greatest partnerships between an actor and a filmmaker in cinematic history. After meeting in the early 1990s in New York City, where Linklater saw Hawke in a play that co-starred their mutual friend Anthony Rapp, Hawke and Linklater have worked together on the beloved “Before” trilogy, the decade-spanning “Boyhood,” and experimental indie hits such as “Tape” and “Waking Life.”But for their ninth collaboration, which has been a dozen years in the making, Hawke and Linklater have chosen to examine the end of an artistic partnership. “Blue Moon,” directed by Linklater and written by Robert Kaplow, premieres in theaters Friday. It follows 20th-century lyricist Lorenz “Larry” Hart (Hawke) as he crashes the opening night party for “Oklahoma!,” the hit musical by his former partner, musician Richard Rodgers (Andrew Scott), and Rodgers’ new collaborator, Oscar Hammerstein II (Simon Delaney), at the legendary Sardi’s restaurant in New York City.Starting in 1919 until Hart’s death of pneumonia in 1943, Rodgers and Hart combined their respective geniuses to create a string of musical comedy hits: “My Funny Valentine”; “The Lady Is a Tramp”; “Isn’t It Romantic?”; “My Heart Stood Still”; “Manhattan”; “Bewitched” and “Blue Moon.” In a career-best performance that could very well earn him his third acting nomination at the Academy Awards (and his fifth overall), Hawke captures Hart’s many contradictions as both a brilliant songwriter and an alcoholic with a penchant for self-destructive behavior.“We always talked about this film as a little howl into the night of an artist being left behind. Not only by the times changing — ‘Oklahoma!’ is the future; his kind of music is the past — but his partner’s leaving him,” Linklater told NBC News in a joint interview with Hawke. “There’s a lot of movies about romantic breakups almost to the point that there’s kind of a similarity there, but not enough films about artistic breakups, which are so complex. Because, in this case, it’s not about the art. It’s really about Larry’s life and his addictions, his problems. He’s made himself hard to work with, and it’s just heartbreaking to see that relationship coming to an end.”Richard Linklater directs scene of “Blue Moon.”Sabrina Lantos / Sony Pictures ClassicsHawke noted that “there’s an intimacy to artistic relationships” that is difficult to articulate. “The relationship with Rodgers is the most important relationship in his life. It’s almost beyond a lover,” he said of Hart, whose working relationship with Rodgers spanned more than 1000 songs. “So to lose that is to lose a huge aspect of yourself, of your professional life, of your self-esteem — it’s all coming apart at its very foundations, because his whole identity is wrapped up in his relationship with Rodgers.”Linklater, 65, first sent Hawke, 54, an early draft of Kaplow’s screenplay a dozen years ago, but Linklater said he felt Hawke was still too young — and, as the director joked, “too good-looking” — to play Hart in the final months of his life. Every few years, they would pull out the script and workshop the dialogue, which was crafted to gradually reveal details about Hart’s personal and professional lives. When the time came to finally step into Hart’s shoes, after years of researching the lyricist on his own time, Hawke joked that he was “stripped” of all of his “vanity.” The nearly 6-foot actor was made to look a foot shorter; given a balding, combover haircut; and was forced to adopt a completely new diction and set of mannerisms.“Him perceiving himself as diminutive in status was essential to the way he interacted with the world. There’s a lot of people that talk a lot that are kind of blowhards, and they’re trying to dominate. Larry’s not trying to dominate. He’s trying to be seen,” Hawke explained. “If he’s not talking, if he’s not the smartest person in the room, if he’s not the funniest, if he’s not the most insightful, nobody notices him — that’s how he feels. He feels tossed away sexually, like he’s not a viable romantic interest for anyone. So things like the comb over, the bad skin, the awkward body language — all that stuff was essential to how he perceived himself so that the audience could understand who Larry was.”In the April 2013 edition of The Atlantic, writer Robert Gottlieb reported that many of Hart’s contemporaries knew he was gay, but he still went to great lengths to try to conceal his sexuality. While writing “Blue Moon,” Kaplow got ahold of 11 letters addressed to Hart from a young woman named Elizabeth, who was a student at Yale University. The screenwriter chose to dramatize that relationship by having Elizabeth (played by Margaret Qualley) show up at Sardi’s on the opening night of “Oklahoma!” to meet Hart, a man more than twice her age who had become infatuated with her.Andrew Scott and Ethan Hawke in “Blue Moon.”Sabrina Lantos / Sony Pictures Classics“I found that such an interesting part because today we forget that to be gay in the ’40s is to be underground. Your sexuality is against the f—ing law. You could be arrested,” Linklater said. “So even the people who worked with him, Larry’s sexuality was never on the table. Rogers never referenced it.”Linklater found there was something “touching but very complex” about the short life of Hart, who died in 1943 at age of 48.“It was a tough time to be around, but then he was born at the right time to do what he does with his gift, to write a thousand songs. They were doing so many shows,” he added. “So we benefit from that, that Larry Hart was alive at this time, but he suffered like so many because of the time he was in.”Hawke said for his interpretation of Hart, “the pain of losing Rodgers is so great and so significant” that “he can’t actually absorb the impact of what’s happening to him.” Instead, “he’s distracting himself with a new wound”: his sexuality.“He believes that an aspect of him is heterosexual, and he could live a normal life, and he sees her as a path to rescue,” Hawke said of Hart’s view of Elizabeth. “He has so much work to do before he’s the partner that Rodgers wants — this guy who’s showing up on time — and he’s not going to do that work. Elizabeth is another wonderful, glorious distraction like the alcohol.”Hawke and Linklater acknowledged the irony of telling a story about an artistic breakup at a time when their own creative partnership has never been stronger. But whereas Hart and Rodgers worked only with each other for a quarter-century, Hawke said he and Linklater have “been lucky that we are not the only well we draw water from.”“We’ve changed because having grown children changes you, time changes you, politics changes you. You have a different relationship to the community as an older person than you do as a younger person,” Hawke said of how his relationship with Linklater has evolved over time. “But the thing that probably would surprise people the most, what’s remarkable about it, is how consistent it’s been. We started talking in 1992, and we just kept talking.”Linklater concurred, adding that he and Hawke have always been “really simple, in that we just want to do the work” at hand. “No matter what’s going on, our priority is seemingly working and making movies, expressing ourselves. I think if I had become a raging alcoholic, or vice versa, the partnership would’ve drifted,” Linklater said with a laugh. “We’re lucky that 30 years later, we’re still on a similar track, I guess, until you’re not. That’s why this film about an artistic breakup is heartbreaking because it’s like, ‘Oh yeah, things do come to an end.’”Max GaoMax Gao is a freelance entertainment and sports journalist based in Toronto. He has written for NBC News, The New York Times, the Los Angeles Times, Sports Illustrated, The Daily Beast, Harper’s Bazaar, Elle, Men’s Health, Teen Vogue and W Magazine. 
October 13, 2025
Oct. 13, 2025, 10:09 AM EDTBy Chantal Da SilvaAs Israeli hostages are freed and Palestinian prisoners and detainees released — and after President Donald Trump’s lengthy address to Israel’s parliament on Monday — focus is shifting to what comes next. Some of the longest applause for Trump’s speech came when he said that virtually the whole region had endorsed a plan for Gaza to be demilitarized and Hamas to disarm — key elements of his 20-point plan that have yet to actually be agreed upon. Now that phase one of his plan is being executed, negotiators and neighboring countries will watch whether key points of Trump’s proposal will be accepted by both Israel and Hamas in talks on the next phases.International Red Cross vehicles transport the second batch of released Israeli hostages from Deir al Balah in central Gaza on Monday. Bashar Taleb / AFP via Getty ImagesLast few daysA ceasefire came into effect in Gaza on Friday at noon local time, (5 a.m. ET), after the first phase of Trump’s plan was agreed by Israel and Hamas, bringing relative calm to the enclave for the first time in months since the last truce collapsed in March. Under the first phase of Trump’s plan, 20 living hostages were handed over to Israel on Monday. The remains of a further 28 hostages held by Hamas were expected to be released within 72 hours, although only four were initially, much to the disappointment of families.Israel also pledged to release 250 convicted prisoners and 1,700 Palestinians detained since Oct. 7. Over 150 of the freed prisoners were deported to Egypt.More aid has begun to flow into the enclave in recent days, although it falls far short of what aid workers say is necessary. Now what?Palestinians head north along al-Rashid Street towards Gaza City, Gaza, on Sunday.Ahmad Salem / Bloomberg via Getty ImagesHamas has long asserted that it would not release the last of the hostages until Israeli groups leave Gaza entirely, but having agreed to the first phase of Trump’s plan, the militant group is relying on guarantees from Trump that a full withdrawal will eventually happen. When and if Israel withdraws fully remains unclear. Meanwhile, it is also unclear whether Hamas, which has ruled Gaza since 2007, will agree to a key stipulation of Trump’s overall plan, as well as a crucial demand from Israel — that it disarm. Hamas has long refused calls to lay down arms, saying it has a right to armed resistance until Israel ends its occupation of Palestinian territories — and that has been a key sticking point in talks to negotiate an end to Israel’s offensive in Gaza.In an interview with Al Jazeera on Oct. 9, senior Hamas official Osama Hamdan said that no Palestinian would accept surrendering weapons and that the people of Gaza were in greater need than ever of resistance. President Trump talks to reporters on board Air Force One en route to Israel on Sunday.Chip Somodevilla / Getty ImagesThe militant group has agreed to step down from leadership over the territory and relinquish governance to a transitional body of Palestinian technocrats, which would be overseen by an international body, dubbed the “Board of Peace.” This body is expected to be headed by Trump, with former British Prime Minister Tony Blair also named as a possible member of the oversight body. Noting the plan aboard the Air Force One on Monday en route to Israel, Trump said he first wanted to find out whether “Tony would be popular with all.””I like Tony, I’ve always liked Tony, but I want to find out that he’s an acceptable choice to everybody,” he added. The idea of Blair joining the board has already drawn early criticism, with his reputation in the region shadowed by his decision to back the U.S.-led 2003 invasion of Iraq — and claims by the U.S. and Britain of Iraq having weapons of mass destruction found to be false. Trump optimistic Speaking aboard Air Force One on his way to Israel on Monday, Trump said he believed “everybody is happy” with his 20-point peace plan. Noting that much of Gaza now resembles a “demolition site” after more than two years of Israel’s offensive in the enclave, Trump said cleanup efforts would begin “pretty much immediately.” During his address to the Knesset, Trump also said Israel has won all it can by force. “Now, it is time to translate these victories against terrorists on the battlefield into the ultimate prize of peace and prosperity for the entire Middle East,” he said. In Gaza, Palestinians across the enclave balanced their hopes for peace against fears that the ceasefire won’t hold, as many return to the areas where their homes once stood. “Everything is gone; no necessities of life remain,” one man told NBC News. “So, why do you live for? Our money, our homes that we worked hard for years — it’s all gone,” he said. “Nothing is left.”Chantal Da SilvaChantal Da Silva reports on world news for NBC News Digital and is based in London.The Associated Press contributed.
Comments are closed.
Scroll To Top
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics
© Copyright 2025 - Be That ! . All Rights Reserved